-
14801por Lui, Grace, Yip, Terry, Yuen, Becky, Sze, Alex, Hui, Yee-tak, Tse, Yee-Kit, Wong, Vincent, Wong, Grace“…All patients with HBV/HIV co-infection and HBV mono-infection treated with antiviral therapy in public hospitals in Hong Kong from 2000 to 2017 were identified from an electronic database. Patients with hepatitis C virus (HCV) infection, HCC diagnosed within six months, or follow-up less than 6 months were excluded. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14802por Malek, Alexandre, Nieto, Yago, Szvalb, Ariel D, Siddiqui, Shaheer, Shafi, Mehnaz A, Hwang, Jessica P, Raad, Issam I, Torres, Harrys A“…Four patients (67%) had a remote history (≥24 months) of other potential risk factors besides ibrutinib that could contribute to HBVr, including the use of direct-acting antivirals for hepatitis C co-infection (1 pt), hematopoietic cell transplant (HCT) (1 pt) and rituximab use (4 patients). …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14803por Michienzi, Sarah M, Cai, Jiaqi, Harris, Cydnee, Kim, Sean, Patel, Nimish, Badowski, Melissa E, Chan, Juliana, Martin, Michelle T, Schriever, Christopher A“…BACKGROUND: Both human immunodeficiency virus (HIV) and hepatitis C virus (HCV) can adversely affect CD4 cell count. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14804por Go, Gabriella, Vigil, Karen J, Parisot, Paul, Vu, Trung, Taylor, Barbara, Jain, Mamta“…Amongst these (n = 89), significant differences were observed with race (P = 0.039), age (P = 0.001), patients identified as MSM/Bisexuals (P = 0.047), diabetes mellitus (DM) (P = 0.01) and hepatitis C virus (HCV) coinfection (P ≤ 0.001). Compared with Whites, Blacks are less likely to have ALD (95% CI 0.27, 0.79, P = 0.004), and those age 40–49 (95% CI 1.28, 10.92, P = 0.016) and >50 (95% CI 1.63, 15.54, P = 0.005) were more likely. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14805por Assoumou, Sabrina A, Wang, Jianing, Nolen, Shayla, Eftekhari Yazdi, Golnaz, Mayer, Kenneth H, Puro, Jon, Salomon, Joshua A, Linas, Benjamin P“…BACKGROUND: Federally qualified health centers (FQHCs) serve diverse communities in the United States (US) and could function as important venues to manage hepatitis C virus (HCV) infections. Little is known on HCV outcomes in underserved communities as most of the current data are derived from clinical trials, commercially insured patients, or small health center samples. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14806“…We then assessed for differences in hepatitis C (HCV) and HIV serostatus, length of stay (LOS), insurance status, total hospital charges, and rates of valve surgery between the two groups. …”
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14807por Bailin, Samuel, McGinnis, Kathleen, McDonnell, Wyatt J, So-Armah, Kaku, Wellons, Melissa, Doyle, Margaret, Mallal, Simon, Justice, Amy, Freiberg, Matthew, Koethe, John“…We used multivariate logistic regression models adjusted for age, gender, body mass index, race/ethnicity, unhealthy alcohol use, hepatitis C, CMV status, and viral suppression stratified by HIV status to identify T-cell subsets associated with diabetes in PWH and uninfected. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14808“…BACKGROUND: Hepatitis B virus, together with hepatitis C virus, has been recognized as the leading causes of hepatocellular carcinoma (HCC). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14809por Tsai, Wei-Lun, Wang, Chih-Feng, Cheng, Jin-Shiung, Chen, Wen-Chi, Bair, Ming-Jong, Lo, Ching-Chu“…BACKGROUND: Sofosbuvir (SOF)-based regimens achieve excellent efficacy and safety in the treatment of chronic hepatitis C (CHC) with various genotypes. There are few real-world instances of the use of SOF-based regimens to treat genotype 2 CHC. …”
Publicado 2020
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14810por Harding, B. N., Whitney, B. M., Nance, R. M., Ruderman, S. A., Crane, H. M., Burkholder, G., Moore, R. D., Mathews, W. C., Eron, J. J., Hunt, P. W., Volberding, P., Rodriguez, B., Mayer, K. H., Saag, M. S., Kitahata, M. M., Heckbert, S. R., Delaney, J. A. C.“…Potential risk factors included: age, sex, race/ethnicity, body mass index, smoking status, hazardous alcohol use, illicit drug use, hepatitis C virus (HCV) coinfection, estimated glomerular filtration rate (eGFR), CD4 cell count, viral load, ART use and time in care at CNICS site. …”
Publicado 2020
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14811“…We have selected the hepatitis C virus (HCV) as a model viral pathogen to demonstrate how model membrane platforms can aid antiviral drug discovery and development. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14812por Rapoport, Alison B, Fine, Danielle, Manne-Goehler, Jennifer, Herzig, Shoshana J, Rowley, Christopher F“…RESULTS: Of 234 patients, over half were male (57%; N = 134), 78% white (N = 183), 17% homeless (N = 37), 88% had public insurance (N = 210); 53% had a history of Hepatitis C infection (N = 124), most with untreated or unknown infection status (86%; N = 107). …”
Publicado 2017
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14813por Deutsch, Liat, Houri, Inbal, Ben-Ari, Ziv, Shlomai, Amir, Veitsman, Ella, Cohen-Ezra, Oranit, Issachar, Assaf, Mor, Orna, Gozlan, Yael, Bruck, Rafael, Menachem, Yoram, Zelber-Sagi, Shira, Katchman, Helena, Shibolet, Oren“…BACKGROUND: Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease and hepatocellular carcinoma. …”
Publicado 2020
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14814por Bell, Christopher E., Botteman, Marc F., Gao, Xin, Weissfeld, Joel L., Postma, Maarten J., Pashos, Chris L., Triulzi, Darrell, Staginnus, Ulf“…A literature-based decision-analytic model was developed to assess the economic costs and clinical outcomes associated with the use of AP and PC treated with the IBS for several conditions and procedures that account for a considerable proportion of the platelet usage in the United States: acute lymphocytic leukemia, non-Hodgkin's lymphoma, coronary artery bypass graft, and hip arthroplasty Risks of infection with HIV, hepatitis C virus (HCV), hepatitis B virus, human T-cell lymphotropic virus type 1, or bacterial agents were incorporated into the model. …”
Publicado 2003
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14815por Sarin, Shiv K, Kumar, Manoj, Eslam, Mohammed, George, Jacob, Al Mahtab, Mamun, Akbar, Sheikh M Fazle, Jia, Jidong, Tian, Qiuju, Aggarwal, Rakesh, Muljono, David H, Omata, Masao, Ooka, Yoshihiko, Han, Kwang-Hyub, Lee, Hye Won, Jafri, Wasim, Butt, Amna S, Chong, Chern H, Lim, Seng G, Pwu, Raoh-Fang, Chen, Ding-Shinn“…Chronic hepatitis B virus (HBV) infection caused more than half of the deaths due to cirrhosis in the region, followed by alcohol consumption (20·8%), non-alcoholic fatty liver disease (NAFLD; 12·1%), and chronic infection with hepatitis C virus (HCV; 15·7%). In 2015, HBV accounted for about half the cases of hepatocellular carcinoma in the region. …”
Publicado 2020
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14816por Marcusso, Rosa Maria N., Van Weyenbergh, Johan, de Moura, João Victor Luisi, Dahy, Flávia Esper, de Moura Brasil Matos, Aline, Haziot, Michel E. J., Vidal, Jose E., Fonseca, Luiz Augusto M., Smid, Jerusa, Assone, Tatiane, Casseb, Jorge, de Oliveira, Augusto César Penalva“…HTLV-1-associated diseases, adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraperesis (HAM/TSP), as well as frequent coinfections with human immunodeficiency virus (HIV), hepatitis C virus (HCV), and Strongyloides stercoralis were associated to increased morbidity and mortality of HTLV-1 infection. …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14817por Yau, Alice, Elayaperumal, Pramma, Butala, Ashvin, Bahtiyar, Gul, Rodriguez, Giovanna“…Labs were significant for negative hepatitis B and hepatitis C; several negative anti-smooth muscle, anti-nuclear antibody, centromere antibody, and liver kidney microsomal type 1 antibody; normal levels of ceruloplasmin and alpha 1 anti-trypsin; low iron levels 23 ug/dL (60-180 ug/dL); borderline low IgG 627 mg/dL (700-1600 mg/dL). …”
Publicado 2020
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14818por Bahuguna, Pankaj, Prinja, Shankar, Lahariya, Chandrakant, Dhiman, Radha Krishan, Kumar, Madhumita Prem, Sharma, Vineeta, Aggarwal, Arun Kumar, Bhaskar, Rajesh, De Graeve, Hilde, Bekedam, Henk“…Subsequently, three separate Markov models were used to compute lifetime costs and QALYs for individuals infected with hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). …”
Publicado 2019
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14819por Asemahagn, Mulusew Andualem“…BACKGROUND: Hepatitis B virus(HBV) and hepatitis C virus(HCV) are the main causes of cirrhosis, liver cancer, and death. …”
Publicado 2020
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
14820“…About 72.05% of the patients have inadequate information about risk of hepatitis B, hepatitis C, and HIV due to blood transfusions and only 21.29% of the patients understand the importance of hepatitis B vaccine. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto